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Abstract: Background: The use of 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/-
Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response monitoring
and post treatment surveillance in metastatic melanoma patients has noticeably increased due to signif-
icant improvement of the overall survival rate in melanoma patients. However, determining the dignity
of the findings with increased metabolic activity on FDG-PET/CT can be sometimes challenging and
may need further investigation. Purpose: We aimed to investigate the malignancy rate of indeterminate
findings on FDG-PET/CT in metastatic cutaneous melanoma patients. Methods: This single-center ret-
rospective study included cutaneous melanoma patients who underwent FDG-PET/CT in clinical routine
between 2015 and 2017 with findings reported as indeterminate and therefore requiring further evaluation.
The dignity of the included findings was determined by subsequent imaging and, if required, additional
histopathology. The impact of the outcome on the clinical management was also reported. Results: A
total of 842 FDG-PET/CT reports of 244 metastatic cutaneous melanoma patients were reviewed. Sixty
indeterminate findings were included. Almost half of all indeterminate findings were lymph nodes, lung
nodules and cerebral lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all
malignant lesions were metastases of cutaneous melanoma, while 19% of all malignant lesions could be
attributed to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malig-
nant findings influenced clinical management in 60% of the cases. Conclusion: Indeterminate findings on
FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one
out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings are
melanoma manifestations, however, in a significant percentage, other primary tumors are found. Upon
verification, patient management is changed in most cases.
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Abstract: Background: The use of 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomogra-
phy/Computed Tomography FDG-PET/CT in clinical routine for staging, treatment response mon-
itoring and post treatment surveillance in metastatic melanoma patients has noticeably increased
due to significant improvement of the overall survival rate in melanoma patients. However, de-
termining the dignity of the findings with increased metabolic activity on FDG-PET/CT can be
sometimes challenging and may need further investigation. Purpose: We aimed to investigate the
malignancy rate of indeterminate findings on FDG-PET/CT in metastatic cutaneous melanoma
patients. Methods: This single-center retrospective study included cutaneous melanoma patients
who underwent FDG-PET/CT in clinical routine between 2015 and 2017 with findings reported as
indeterminate and therefore requiring further evaluation. The dignity of the included findings was
determined by subsequent imaging and, if required, additional histopathology. The impact of the
outcome on the clinical management was also reported. Results: A total of 842 FDG-PET/CT reports
of 244 metastatic cutaneous melanoma patients were reviewed. Sixty indeterminate findings were
included. Almost half of all indeterminate findings were lymph nodes, lung nodules and cerebral
lesions. In total, 43.3% of all included findings proved to be malignant. 81% of all malignant lesions
were metastases of cutaneous melanoma, while 19% of all malignant lesions could be attributed
to other primary malignancies, such as lung, breast, thyroid and colorectal cancers. Malignant
findings influenced clinical management in 60% of the cases. Conclusion: Indeterminate findings on
FDG-PET/CT in metastatic cutaneous melanoma patients should be further investigated. Almost one
out of every two indeterminate findings on FDG-PET/CT is malignant. The majority of the findings
are melanoma manifestations, however, in a significant percentage, other primary tumors are found.
Upon verification, patient management is changed in most cases.
Keywords: positron emission tomography; computed tomography; melanoma; immunotherapy
1. Introduction
Cutaneous melanoma causes 90% of skin cancer mortality [1] and is the leading cause
of skin cancer-related mortality [2]. Over the past decades, the incidence of cutaneous
melanoma has increased in many Western countries, affecting both younger and older
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populations [2,3], and becoming the most rapidly increasing cancer in Caucasian pop-
ulations [4]. The number of cases of cutaneous melanoma is predicted to continue to
increase for decades, particularly in Caucasians with excessive sun exposure [1]. However,
significant improvements in the diagnosis and treatment of cutaneous melanoma have
changed the context of this disease [5]. Immune checkpoint inhibitors (ICI), including
anti-PD1 and anti-CTLA4, as well as targeted therapy with BRAF/MEK inhibitors for
BRAF mutant disease have significantly prolonged the survival of patients with metastatic
melanoma and are therefore deemed standard of care [6]. Due to the prolonged, sustainable
responses, imaging-based surveillance of advanced stage III/IV disease is essential for
early assessment of treatment efficacy, as well as locoregional and distant metastasis [3].
18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed Tomog-
raphy (FDG-PET/CT) has shown an additional value over Computed Tomography (CT)
for staging in melanoma patients [7]. According to the 2019 European consensus-based
interdisciplinary guideline update for cutaneous melanoma, whole-body FDG-PET/CT
examinations in combination with brain MRI are recommended from stage IIC to stage
IV (8th version of the American Joint Committee on Cancer AJCC classification) [1]. FDG-
PET/CT is considered an effective tool for staging and treatment response assessment in
metastatic melanoma patients [8]. However, a low specificity for initial locoregional lymph
node metastases in early stages was observed [9].
Due to the mechanism of action of immune checkpoint inhibitors, the use of con-
ventional morphological criteria such as Response Evaluation Criteria in Solid Tumors
(RECIST) can be challenging. FDG-PET/CT can be used to assess the treatment response
using morphologic and metabolic response criteria adapted to immunotherapy [10]. In
order to correctly assess response to treatment, atypical response patterns such as pseudo-
progression or hyperprogression [11–14] and immune-related adverse events [15–17] have
to be taken into account.
After surgical or systemic treatment, a structured follow-up by FDG-PET/CT is
required for early detection of relapses and secondary primary melanomas [1,2], although a
consensus is still lacking regarding the timing of FDG-PET/CT [7]. A stage-based follow-up
scheme by FDG-PET/CT from stage IIC to stage IV (8th version of AJCC classification) is
recommended by the European guidelines 2019 [1].
Taking into consideration the significant improvement of the overall survival in
melanoma patients [10], and the inclusion of FDG-PET/CT into the European guidelines
2019 for cutaneous melanoma, FDG-PET/CT has been increasingly used for staging, treat-
ment response monitoring and post treatment surveillance in advanced melanoma [18].
Furthermore, given the known atypical response patterns under immunotherapy [11–14],
a differentiation between increased metabolic activity due to tumor progression and in-
creased metabolic activity due to, e.g., the effects of immune checkpoint inhibitors on
FDG-PET/CT, can be challenging. It therefore appears relevant to quantify the malig-
nancy risk of indeterminate findings reported on the FDG-PET/CT in metastatic cutaneous
melanoma patients in clinical routine, and so further evaluation is required. Therefore, we
aimed to investigate the malignancy rate of indeterminate findings on FDG-PET/CT at




This study cohort included patients with histopathologically proven cutaneous melanoma
treated at the Department of Dermatology of the University Hospital Zurich in Switzerland
who underwent FDG-PET/CT as part of clinical routine for staging and/or treatment
response assessment and/or post treatment surveillance.
This single-center retrospective study was approved by the local ethics committee
(PB_2017-00181) and conducted in compliance with Good Clinical Practice (GCP) rules and
the Declaration of Helsinki.
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2.2. FDG-PET/CT Acquisition
All FDG-PET/CT scans were performed as part of clinical routine between 1 January
2015 and 31 December 2017 at the Department of Nuclear Medicine of the University
Hospital Zurich, Switzerland, according to the department’s standard protocol.
Patients were asked to fast at least for 4 h prior the intravenous 18F-FDG-administration.
A blood glucose level below 160 mg/dl at the time of 18F-FDG injection was mandatory. Im-
age acquisition began 60 min after the administration of a body mass index (BMI)-adapted
18F-FDG dose. All examinations were performed on General Electric GE Discovery MI
(DMI) and Discovery 690 PET/CT scanners (General Electrics GE Healthcare, Boston,
MA, USA).
In accordance with our protocol, FDG-PET/CT scans were performed from the vertex
of the skull to the thighs. Whole body FDG-PET/CT scans were performed only if the
primary melanoma was located in the lower extremities. A CT scan without contrast
medium was performed first for attenuation correction (matrix size 512 × 512; field of view
50 cm; slice thickness 3.75 mm) and immediately followed by the PET acquisition in six
or seven bed positions (patient size adapted), with 2.5 min per bed position (matrix size
256 × 256; field of view 70 cm) using iterative reconstructions (Ordered Subset Expectation
Maximization (OSEM); Block Sequential Regularized Expectation Maximation (BSREM)).
2.3. FDG-PET/CT Image Analysis
The analysis of fused FDG-PET/CT data displayed in transversal, sagittal and coronal
planes was not part of our investigation but was previously carried out in clinical routine
by experienced physicians board certified in radiology and nuclear medicine using GE
Advantage Workstations 4.4-7.
2.4. Lesion Selection
We retrospectively reviewed the reports of all FDG-PET/CT scans performed in clin-
ical routine between 1 January 2015 and 31 December 2017. A lesion was considered as
indeterminate on the FDG-PET/CT whenever it could not be unequivocally character-
ized as benign nor malignant by the reporting physician and additional imaging was
recommended for further evaluation.
Qualitative criteria were used in the reviewed FDG-PET/CT reports by the reporting
nuclear physicians for the assessment of indeterminate findings.
Among our qualitative criterias for the assessment of indeterminate findings either the
evidence of focal, not physiological, FDG-uptake without a clearly identifiable morphologi-
cal correlate (in brain, bone, colon, kidney, liver, prostate, small bowel) or focal, not physi-
ological, FDG-uptake with a subtle morphological correlation (in breast, cutis/subcutis,
head/neck, mediastinum, thyroid gland). The following criteria were used for lymph
nodes: a focal FDG-uptake without any clearly suspicious morphological criterion on
native Computed Tomography scan (i.e., enlarged in short axis diameter, round in shape
and no internal fat attenuation) or one morphological suspicious criterion without focal
suspicious FDG-uptake. Small solid lung nodules with subtle FDG-uptake were included.
The following morphological criteria were used with regards to solid lung nodules on
native Computed Tomography scan: sharp margins (no lobulation, no spiculation), no
calcification and smaller than 6 mm in size.
We subsequently recorded if the imaging requested by the reporting nuclear physi-
cian (i.e., ultrasound guided biopsy, mammography, computed tomography, magnetic
resonance imaging, colonoscopy and bronchoscopy) was performed. Therefore, all re-
ports from the interdisciplinary tumor board for melanoma, as well as any imaging per-
formed subsequently between the date of the corresponding FDG-PET/CT scan and
30 November 2020, were reviewed. The recommended biopsy (guided by ultrasound,
bronchoscopy, colonoscopy or after mammography) was performed 26.7 ± 19.1 days (aver-
age ± standard deviation) after the corresponding indeterminate finding was reported on
the FDG-PET/CT scan, while a radiological follow-up (Computed Tomography or Mag-
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netic Resonance Imaging) was carried out 75.9 ± 49.9 days (average ± standard deviation)
after the FDG-PET/CT scan.
Each included indeterminate lesion was then classified as benign or malignant based
on the results of subsequent imaging and, when available, additional histopathology.
Given the short time window of radiological follow-up, we decided to put the results
of additional imaging and histopathology into the clinical context and investigate in close
cooperation with the Department of Dermatology of the University Hospital Zurich if the
result of the required evaluation had a long-term impact on clinical management (i.e., until
30 November 2020). This evaluation was based on clinical reports and interdisciplinary
tumor board decisions.
2.5. Statistical Analysis
All statistical computations were performed using the Statistical Package for the
Social Sciences software (SPSS Statistics Version 25.0.0.1; International Business Machines
Corporation IBM, Armonk, NY, USA). Descriptive statistical analyses were carried out.
Chi-square tests were used for the calculation of association between our parameters.
Statistical significance was accepted at p < 0.05.
3. Results
3.1. Patient Population
The reports of 842 FDG-PET/CT scans performed in clinical routine between 1 January
2015 and 31 December 2017 for staging and/or treatment response assessment and/or post
treatment surveillance at the Department of Nuclear Medicine of the University Hospital
Zurich were retrospectively reviewed.
Among these 842 FDG-PET/CT reports of 244 metastatic melanoma patients,
90 indeterminate findings were observed, although in some cases no documentation on the
recommended imaging could be noted retrospectively either because the required imag-
ing after FDG-PET/CT was declined by the patient (n = 4) or, most probably, performed
externally (n = 26).
Consequently, 60 indeterminate findings in 60 different melanoma patients (61.7% men,
n = 37; 38.3% women, n = 23; mean age 67.4 years) were included. Each patient had only
one finding on FDG-PET/CT requiring further imaging-based evaluation (Figure 1).
3.2. Indeterminate Findings on FDG-PET/CT Scan
The most frequent indeterminate findings on the FDG-PET/CT were lymph nodes
18.3% (n = 11), lung nodules 15.0% (n = 9) and brain lesions 13.3% (n = 8) constituting alto-
gether 46.6% (n = 28) of all included findings. The fourth and fifth most recurrent findings
requiring further evaluation were liver lesions 11.7% (n = 7) and cutaneous/subcutaneous
lesions 10.0% (n = 6) (Figure 2).
3.3. Additional Imaging Required after FDG-PET/CT Scan
The most commonly recommended additional imaging after FDG-PET/CT was
ultrasound-guided biopsy 33.3% (n = 20), followed by magnetic resonance imaging 31.7%
(n = 19) and computed tomography 20.0% (n = 12), which altogether account for 85% of all
requested further examinations (Figure 2).
3.4. Standard Assessment of Dignity
The dignity of each included lesion was assessed based on radiological follow up (i.e.,
CT or MRI, n = 31, 51.6%) and, whenever available, histopathology (i.e., biopsy guided
by ultrasound, colonoscopy, bronchoscopy or based on mammography, n = 29, 48.4%)
(Table 1).
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Figure 1. Flowchart showing lesion selection with all included and excluded lesions. The reports of all FDG-PET/CT scans
(n = 842) performed between January 2015 and December 2017 in melanoma patients (n = 244) in clinical routine either for
staging, treatment response assessment or post treatment surveillance were considered. Initially, 90 indeterminate findings
on the FDG-PET/CT requiring additional imaging for further evaluation were retrospectively found in the reviewed reports.
Lesions were excluded either when patients declined additional imaging (n = 4) or no documentation on the recommended
imaging after FDG-PET/CT could be found (n = 26). In total, 60 indeterminate lesions were included. All included patients
(n = 60) with histopathologically proven melanoma who were treated at the Department of Dermatology of the University
Hospital Zurich—each patient with one indeterminate finding on the FDG-PET/CT.
3.5. Outcome of Required Additional Imaging after FDG-PET/CT Scan
When assessing the malignancy rate of various organs, only 27.3% of the included
indeterminate lymph nodes were found to be malignant, while 33.3% of the indeterminate
lung nodules, 62.5% of the indeterminate cerebral lesions and 71.4% of the indeterminate
liver lesions were classified as malignant. All indeterminate findings in the small bowel,
kidney, mediastinum and prostate proved to be benign; however, 50% of the findings in the
bone, colon and head/neck were malignant. Finally, 66.7% of the indeterminate findings
located in the breast and 33.3% of the cutaneous or subcutaneous indeterminate findings
were proven to be malignant. In total, 43.3% (n = 26) of all included findings were found to
be malignant and 56.7% (n = 34) benign (Table 2).
Of all malignant lesions, 81% (n = 21) were metastatic melanoma lesions, while 19%
were additional malignancies: 8% (n = 2) were found to be lung cancer, 4% (n = 1) breast
cancer, 4% (n = 1) thyroid cancer and 4% (n = 1) colorectal cancer, respectively (Figure 2).
Among the patients with additional primary cancers, an indeterminate subcutaneous
nodule was seen in the left breast of an 81-year-old female patient in post treatment surveil-
lance (initially with metastatic cutaneous melanoma stage IV). The reporting physicians
recommended an ultrasound-guided biopsy for further evaluation. The biopsy revealed an
invasive ductal breast cancer (Figure 3) (Case 1).
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Figure 2. Sankey plot showing, per included indeterminate finding on the FDG-PET/CT (n = 60), on the far left, (a) location
per organ; in the middle, (b) recommended imaging for further evaluation; and the far right, (c) outcome of additional
imaging. Benign findings are displayed in green, malign findings in red arrows. (a) Location per organ (on the left from the
bottom to the top): thyroid (n = 4; 5.0%, small bowel (n = 1; 1.7%), prostate (n = 1; 1.7%), mediastinum (n = 1; 1.7%), lymph
node (n = 11; 18.3%), lung (n = 9; 15.0%), liver (n = 7; 11.7%), kidney (n = 1; 1.7%), head/neck (n = 2; 3.3%), cutis/subcutis
(n = 6; 10.0%), colon (n = 4; 6.7%), breast (n = 3; 5.0%), brain (n = 8; 13.3%), bone (n = 2; 3.3%). (b) Recommended imaging (in
the middle from the bottom to the top): ultrasound guided biopsy (n = 20; 33.3%), mammography (n = 3; 5.0%), magnetic
resonance imaging (n = 19; 31.7%), computed tomography (n = 12; 20.0%), colonoscopy (n = 4; 6.7%), bronchoscopy (n = 2;
3.3%). (c) Result (on the right from the bottom to the top): thyroid cancer (n = 1; 1.7%), melanoma metastasis (n = 21; 35.0%),
lung cancer (n = 2; 3.3%), colorectal cancer (n = 1; 1.7%), breast cancer (n = 1; 1.7%), benign (n = 34; 56.7%).
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Table 1. The dignity of all included lesions requiring further evaluation after the FDG-PET/CT scan (n = 60) was as-
sessed based on radiological follow up (i.e., Computed Tomography (CT) or Magnetic Resonance Imaging (MRI)) and/or






Biopsy Guide by a
Bronchoscopy, b Colonoscopy
or Based on c Mammography
Total
Lymph node 3 7 1a 11
Liver 6 1 0 7
Thyroid 0 4 0 4
Breast 1 1 1c 3
Cutis/Subcutis 3 3 0 6
Brain 8 0 0 8
Head/Neck 0 2 0 2
Lung 8 0 1a 9
Colon 0 0 4b 4
Small bowel 1 0 0 1
Bone 2 0 0 2
Kidney 0 1 0 1
Mediastinum 0 0 1a 1
Prostate 0 1 0 1
Total 31 20 9 60
The table shows, on a per organ basis, how often a radiological follow up and/or biopsy was recommended for all included lesions
(n = 60). (c): The indication for ultrasound guided biopsy was not primarily based on FDG-PET/CT, but only secondarily after an abnormal
recommended mammography in contrast to the other biopsies listed (n = 26), which were recommended based on FDG-PET/CT findings.
Table 2. All included lesions reported as indeterminate on FDG-PET/CT (n = 60) were classified as benign or malignant
based on the outcome of the required further evaluation (i.e., radiological follow up and/or histopathology).
Organ






Lymph node 8 3 11
Liver 2 5 7
Thyroid 2 2 4
Breast 1 2 3
Cutis/Subcutis 4 2 6
Brain 3 5 8
Head/Neck 1 1 2
Lung 6 3 9
Colon 2 2 4
Small bowel 1 0 1
Bone 1 1 2
Kidney 1 0 1
Mediastinum 1 0 1
Prostate 1 0 1
Total 34 26 60
The table shows the dignity of all included indeterminate findings per organ (first column from right), i.e., how often per considered organ
(first column from left) an indeterminate finding on FDG-PET/CT was proved to be benign (second column from left) or malignant (third
column from left) after further evaluation.
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Figure 3. An 81-year-old female patient initially with metastatic cutaneous melanoma stage IV (pT2a N3 M1b).
(A) Maximum intensity projection (MIP); (B) Computed Tomography (CT) axial of chest; (C) Positron Emission Tomogra-
phy( PET) axial of chest; (D) Fused images PET/CT axial of chest. First row: FDG-PET/CT performed for surveillance after
treatment without evidence of metabolically active recurrence, nodal or distant metastasis. Contamination at injection site
cubital on the right upper extremity. Second row: Six months later, a morphologic and metabolic progredient subcutaneous
nodule in the left breast was seen (yellow arrow). An ultrasound-guided biopsy was subsequently recommended for further
evaluation. The biopsy revealed an invasive ductal breast cancer.
A focal FDG-uptake with wall thickening in the rectosigmoidal colon was also ob-
served in a 72-year-old male patient with metastatic cutaneous melanoma stage IIIC during
treatment response assessment. A rectoscopy was subsequently performed based on the
recommendation of the reporting physicians. The biopsy revealed a well-differentiated
adenocarcinoma of the colon (Figure 4) (Case 2).
3.6. Impact of Required Additional Imaging on Clinical Management
Overall, the outcome of additional imaging required after FDG-PET/CT influenced
clinical management in 25% of all cases (n = 15, p = 0.00 < 0.05), leading either to initiation
of a new treatment 18.3% (n = 11), abort of ongoing therapy 5.0% (n = 3) or a change in
treatment 1.7% (n = 1).
Almost 60% (n = 15) of all findings found to be malignant after complementary
evaluation (n = 26) showed an impact on clinical management (Figure 5) (Figure 3).
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Figure 4. A 72-year-old male patient initially with metastatic cutaneous melanoma stage IIIC (T0 N2b M0). (A) Maximum
intensity projection (MIP); (B) Computed Tomography (CT) axial of pelvis; (C) Positron Emission Tomography (PET) axial
of pelvis; (D) Fused images PET/CT axial of pelvis. First row: FDG-PET/CT performed for extended staging after left
axillary lymphadenectomy without evidence of metabolically active melanoma, nodal or distant metastasis. Second row:
Follow-up for treatment response assessment under anti-PD1 monotherapy. Three months after treatment initiation, a new
metabolically active wall thickening of the rectosigmoidal colon was seen (yellow arrow). A rectoscopy was subsequently
recommended for further evaluation. The biopsy revealed a well-differentiated adenocarcinoma of the colon.
3.7. Impact of FDG-PET/CT Indication on Results of Recommended Additional Imaging
Of all FDG-PET/CT scans, 51.7% were performed for staging (n = 31), 33.3% (n = 20)
for post treatment surveillance and 15.0% (n = 9) for treatment response assessment.
Of all indeterminate findings on FDG-PET/CT performed for staging, treatment
response assessment and post treatment surveillance, 51.6%, 55.6% and only 20% were
found to be malignant, respectively (p = 0.04 < 0.05). Of all malignant lesions, 64.0% (n=16)
were found during staging. Eighty percent of findings (n = 16) reported as indeterminate
on FDG-PET/CT during post treatment surveillance were found to be benign (Figure 3).
Diagnostics 2021, 11, 883 10 of 14
Figure 5. Sankey plot showing, per included indeterminate finding (n = 60), on the far left, (a) indication of FDG-PET/CT
scan it was reported on as indeterminate; in the middle, (b) result of additional imaging; and on the far right, (c) impact
of additional imaging on clinical management. Benign findings are displayed in green, malignant findings in red arrows.
(a) Indication (on the left from the bottom to the top): treatment response assessment (n = 9; 15.0%), staging (n = 31; 51.7%)
and follow-up (n = 20; 33.3%). (b) Result (in the middle from the bottom to the top): thyroid cancer (n = 1; 1.7%), melanoma
metastasis (n = 21; 35.0%), lung cancer (n = 2; 3.3%), colorectal cancer (n = 1; 1.7%), breast cancer (n = 1; 1.7%), benign (n = 34;
56.7%). (c) Impact (on the right from the bottom to the top): therapy stop (n = 3; 5.0%), therapy start (n = 11; 18.3%), therapy
change (n = 1; 1.7%) and no influence on therapy (n = 45; 75%).
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4. Discussion
This monocentric retrospective study was intended to investigate the malignancy rate of
indeterminate findings on FDG-PET/CT along the pathway of metastatic melanoma patients
at the levels of staging, treatment response assessment and post treatment surveillance.
Our results suggest that lymph nodes, lung nodules and brain lesions were the most
frequent indeterminate findings on FDG-PET/CT. Ultrasound-guided biopsy, computed
tomography and magnetic resonance imaging together accounted for 85% of all requested
additional imaging after FDG-PET/CT.
A very significant association between indication of FDG-PET/CT and outcome of
recommended imaging was observed. Almost half of the indeterminate findings on FDG-
PET/CT during staging and treatment response assessment in melanoma patients were
found to be malignant. The vast majority of malignant findings were melanoma metastasis,
followed by additional primary tumors such as lung, breast, colon and thyroid cancer.
Interestingly, most of the indeterminate findings on FDG-PET/CT during post treatment
surveillance were found to be false positive, with lymph nodes and lung nodules being by
far the most common false positive findings on FDG-PET/CT.
Our investigation also demonstrated a significant impact of the additional imaging
required after FDG-PET/CT on clinical management in melanoma patients. Approximately
60% of all malignant findings lead either to treatment change, treatment stop or initiation
of new therapy.
Alongside the benefits of imaging-based surveillance, potential false positive findings
with additional healthcare management and costs in melanoma patients undergoing regular
follow-ups have also been recently discussed [19]. Our first significant observation was that
lymph nodes and lung nodules were the most frequent indeterminate findings on FDG-
PET/CT that required additional imaging, but at the same time, were mostly false positives,
particularly in post treatment surveillance. In 2019, Nijhuis et al., aimed to quantify false
positive and incidental findings from annual surveillance imaging based on baseline CT
or PET/CT and two annual surveillance scans. They observed 124 findings reported as
suspicious of melanoma recurrence, and non-melanoma-related findings requiring further
action in at least half of all 154 included stage III melanoma patients undergoing annual
surveillance imaging. Interestingly, 88% (109 of 124) of these findings were found to be
benign based on histopathology, subsequent imaging or clinical follow-up [19], which
is in keeping with our results. A very significant association between the indication of
FDG-PET/CT and the outcome of recommended imaging was observed in our population.
Only 20% of all indeterminate findings reported on the FDG-PET/CT scans performed for
post treatment surveillance were malignant in our cohort.
Our second important observation was that approximately 60% of all malignant
findings (i.e., 25% of all included indeterminate findings on the FDG-PET/CT scans) led
either to a change in treatment, stopping of treatment or the initiation of a new therapy.
Pfannenberg et al., reported in 2019 that FDG-PET/CT had an impact on clinical manage-
ment in 37.1% of cases, most frequently from nontreatment strategy to active treatment
after FDG-PET/CT, with the highest rate of treatment changes found after FDG-PET/CT
scans in melanoma patients (up to 46.0%) [20]. Forschner et al., also reported, based on
prospective data published in 2017, that FDG-PET/CT prevented futile surgery by half
(n = 55; 51.4%) of advanced (mainly stage III/IV) melanoma patients initially planned
for radical metastasectomy [21]. The vast majority of malignant findings in our cohort
were melanoma metastases, followed by additional primary tumors such as lung, breast,
colon and thyroid cancer, particularly during staging and treatment response assessment.
Dimitriou et al., described in 2019 hematologic or solid additional primary tumors (such as
breast, thyroid cancer or leukemia) in melanoma patients as an important survival issue,
which have emerged since the significant increase of life expectancy due to recent progress
in diagnosis and treatment of melanoma [22].
Thirdly, we observed that ultimately only a few lesions were reported as indeterminate
in all FDG-PET/CT reports reviewed (proportionally, in one report out of ten), suggesting
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additional imaging was often not required after FDG-PET/CT. Pfannenberg et al., reported
in their prospective study published in 2019 that the greatest impact of FDG-PET/CT on
clinical management of cancer patients was in reducing needs for further imaging and
avoiding invasive tests by comparing intended management before and after FDG-PET/CT.
Based on their German prospective registry data, additional imaging was initially required
in 66.1% before FDG-PET/CT, and only 6.1% of cases after FDG-PET/CT. In addition,
initially planned invasive tests could be avoided in 72.7% of cases after FDG-PET/CT.
Alongside melanoma, Pfannenberg et al., considered several other malignancies such as
lung cancer, lymphoma, prostate cancer and neuroendocrine tumors [20], while we focused
solely on melanoma patients.
Of note, no contrast agent was used during the FDG-PET/CT acquisition according
to our standard protocol for cutaneous melanoma in order to save radiation doses. As
previously mentioned, lymph nodes, lung nodules, brain and liver were the most frequent
locations for indeterminate findings on the FDG-PET/CT scan. Among the indeterminate
liver lesions without evidence of malignancy, either hemangiomas or no morphological
correlates were found. Meningiomas, gliotic changes or no morphological correlate were
found among the indeterminate cerebral lesions without evidence of malignancy. The
included lung nodules were round in shape with no spiculation or lobulation and ≤
6mm in size. The considered lymph nodes were not enlarged and without central fat
attenuation. After further evaluation, the pulmonal and lymphonodal indeterminate
findings without evidence of malignancy were due to inflammatory changes. In light
of these results, the injection of a contrast agent would presumably have, in few cases,
provided additional information making a further workup, possibly including full-dose
CT (e.g., for indeterminate findings in the liver such as hemangiomas) unnecessary. The
potential additional morphological information provided by the administration of contrast
media with regards to indeterminate findings in the small bowel, kidney and prostate,
where all findings were found with no morphological correlate in our cohort, should be
further investigated.
One possible limitation of our study could be the reproducibility of our results. Our
investigations were carried out in a single university center with an interdisciplinary
team and easy access to all imaging and interventional modalities for the evaluation of
indeterminate findings. On the other hand, monocentricity offers advantages of similar
image and report quality thanks to state-of-the-art equipment and experienced specialists,
who weekly participate in a dedicated interdisciplinary tumor board for melanoma. Other
limitations are the retrospective approach and size of our cohort, which could be overcome
by further prospective investigations with larger groups in the future.
5. Conclusions
Indeterminate findings on FDG-PET (including low-dose CT) in metastatic cutaneous
melanoma patients need to be further investigated. Almost one out of every two indeter-
minate findings, either on PET, low-dose CT or both, is malignant. The majority of the
findings are melanoma manifestations; however, in a significant percentage, other primary
tumors are found. Upon verification by follow-up imaging or biopsy, patient management
is changed in most cases.
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Abbreviations
ICI Immune Checkpoint Inhibitors
anti-PD1 anti-Programmed Death-1
anti-CTLA4 anti-Cytotoxic T-Lymphocyte-Associated Protein 4
FDG-PET/CT 18F-2-Fluor-2-desoxy-D-glucose Positron Emission Tomography/Computed
Tomography
CT Computed Tomography
AJCC American Joint Committee on Cancer
RECIST Response Evaluation Criteria in Solid Tumors
GCP Good Clinical Practice
mg Milligram
dl Deciliter
BMI Body Mass Index
GE General Electric
PET Positron Emission Tomography
OSEM Ordered Subset Expectation Maximization
BSREM Block Sequential Regularized Expectation Maximation
SPSS Statistical Package for the Social Sciences
MRI Magnetic Resonance Imaging
DWI Diffusion Weighted Imaging
MIP Maximum Intensity Projection
References
1. Garbe, C.; Amaral, T.; Peris, K.; Hauschild, A.; Arenberger, P.; Bastholt, L.; Bataille, V.; Del Marmol, V.; Dréno, B.; Fargnoli, M.C.;
et al. European Consensus-Based Interdisciplinary Guideline for Melanoma. Part 1: Diagnostics-Update 2019. Eur. J. Cancer 2020,
126, 141–158. [CrossRef] [PubMed]
2. Burns, D.; George, J.; Aucoin, D.; Bower, J.; Burrell, S.; Gilbert, R.; Bower, N. The Pathogenesis and Clinical Management of
Cutaneous Melanoma: An Evidence-Based Review. J. Med. Imaging Radiat. Sci. 2019, 50, 460–469.e1. [CrossRef] [PubMed]
3. Howard, M.D. Melanoma Radiological Surveillance: A Review of Current Evidence and Clinical Challenges. Yale J. Biol. Med.
2020, 93, 207–213. [PubMed]
4. Leiter, U.; Eigentler, T.; Garbe, C. Epidemiology of Skin Cancer. Adv. Exp. Med. Biol. 2014, 810, 120–140. [CrossRef]
5. Dimitriou, F.; Krattinger, R.; Ramelyte, E.; Barysch, M.J.; Micaletto, S.; Dummer, R.; Goldinger, S.M. The World of Melanoma:
Epidemiologic, Genetic, and Anatomic Differences of Melanoma across the Globe. Curr. Oncol. Rep. 2018, 20, 87. [CrossRef]
6. Luke, J.J.; Flaherty, K.T.; Ribas, A.; Long, G.V. Targeted Agents and Immunotherapies: Optimizing Outcomes in Melanoma. Nat.
Rev. Clin. Oncol. 2017, 14, 463–482. [CrossRef]
7. Mittal, B.R.; Malik, D.; Sood, A.; Basher, R.K.; Bhattacharya, A.; Singh, G. Role of 18F-Fluorodeoxyglucose Positron Emission
Tomography/Computed Tomography in Restaging and Prognosis of Recurrent Melanoma after Curative Surgery. World J. Nucl.
Med. 2019, 18, 176–182. [CrossRef]
8. Salvatore, A.; Riccardo, L.; Federico, C.; Daniele, A.P.; Young Aimn Working Group. Clinical Value of PET/CT in Staging
Melanoma and Potential New Radiotracers. Curr. Radiopharm. 2020, 13, 6–13. [CrossRef]
9. Cheng, D.; McNicoll, C.F.; Kirgan, D.; Jones, M.S.; Rivera, M.R.; Doyle, G.M.; De Guzman, M.D.; Baynosa, J.; Hill, C.R.S. The Role
of FDG-PET-CT Is Limited in Initial Staging of Nodal Metastasis for Thin Cutaneous Melanoma. Am. J. Surg. 2021, 221, 737–740.
[CrossRef]
10. Castello, A.; Lopci, E. The Role of PET/CT in the Era of Immune Checkpoint Inhibitors: State of Art. Curr. Radiopharm. 2020, 13,
24–31. [CrossRef]
Diagnostics 2021, 11, 883 14 of 14
11. Decazes, P.; Bohn, P. Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future
Applications. Cancers 2020, 12, 371. [CrossRef]
12. Dittrich, D.; Pyka, T.; Scheidhauer, K.; Lütje, S.; Essler, M.; Bundschuh, R.A. Textural Features in FDG-PET/CT Can Predict
Outcome in Melanoma Patients to Treatment with Vemurafenib and Ipililumab. Nukl. Nucl. Med. 2020, 59, 228–234. [CrossRef]
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